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ABSTRACT:
Microenvironmental factors contribute to the immune dysfunction characterizing  
acute myeloid leukemia (AML). Indoleamine 2,3-dioxygenase 1 (IDO1) is an interferon 
(IFN)-γ-inducible enzyme that degrades tryptophan into kynurenine, which, in turn, 
inhibits effector T cells and promotes regulatory T-cell (Treg) differentiation. It is 
presently unknown whether childhood AML cells express IDO1 and whether IDO1 
activity correlates with patient outcome.
We investigated IDO1 expression and function in 37 children with newly 
diagnosed AML other than acute promyelocytic leukemia. Blast cells were cultured 
with exogenous IFN-γ for 24 hours, followed by the measurement of kynurenine 
production and tryptophan consumption. No constitutive expression of IDO1 protein 
was detected in blast cells from the 37 AML samples herein tested. Conversely, 19 out 
of 37 (51%) AML samples up-regulated functional IDO1 protein in response to IFN-γ. 
The inability to express IDO1 by the remaining 18 AML samples was not apparently 
due to a defective IFN-γ signaling circuitry, as suggested by the measurement of 
signal transducer and activator of transcription 3 (STAT3) phosphorylation. Co-
immunoprecipitation assays indicated the occurrence of physical interactions between 
STAT3 and IDO1 in AML blasts. In line with this finding, STAT3 inhibitors abrogated 
IDO1 function in AML blasts. Interestingly, levels of IFN-γ were significantly higher 
in the bone marrow fluid of IDO-expressing compared with IDO-nonexpressing AMLs. 
In mixed tumor lymphocyte cultures (MTLC), IDO-expressing AML blasts blunted the 
ability of allogeneic naïve T cells to produce IFN-γ and promoted Treg differentiation. 
From a clinical perspective, the 8-year event-free survival was significantly worse in 
IDO-expressing children (16.4%, SE 9.8) as compared with IDO-nonexpressing ones 
(48.0%, SE 12.1; p=0.035).
These data indicate that IDO1 expression by leukemia blasts negatively affects 
the prognosis of childhood AML. Moreover, they speak in favor of the hypothesis that 
IDO can be targeted, in adjunct to current chemotherapy approaches, to improve the 
clinical outcome of children with AML.
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INTRODUCTION
Childhood acute myeloid leukemia (AML) is a 
rare and heterogeneous disease, with an annual incidence 
of 7 cases per million children younger than 15 years 
[1]. Patients’ stratification according to biological 
characteristics and response to induction therapy, together 
with the intensification of conventional chemotherapy 
and advent of better supportive care strategies, have 
improved prognosis, the current 5-year overall survival 
(OS) rates being in the order of 70% [1]. However, 5% 
of children with AML have refractory disease and 30% 
still experience relapse. Allogeneic hematopoietic stem 
cell transplantation (HSCT) can be curative for some 
patients with relapsed AML, who are successfully 
given re-induction chemotherapy [1, 2]. The major 
therapeutic benefit of allogeneic HSCT results from the 
so-called graft-versus-leukemia (GVL) effect, namely, the 
recognition by donor-derived T cells of antigens expressed 
on host malignant cells. The existence of a GVL effect 
is underpinned by the evidence that infusion of donor 
lymphocytes can induce disease remission in patients 
who have relapsed following allogeneic HSCT [3, 4]. 
These findings imply that the stimulation of anti-leukemia 
immunity may be crucial to improve the clinical outcome 
of patients with AML.
Escape from immunosurveillance through 
immunoselection, also known as immunoediting, and 
immunosubversion, i.e., active suppression of the immune 
response, is a hallmark of cancer [5]. The immune 
evasion mechanisms exploited by AML have begun to be 
elucidated but recently, and represent a major hurdle to the 
delivery of effective immunotherapy. AML is a systemic 
disease, and the microenvironment shaped by AML cells 
may differ in many aspects from that of anatomically-
localized, solid malignancies. However, some immune 
escape pathways promoted by AML overlap with those 
fostered by solid tumors, such as expansion of naturally 
occurring CD4+FoxP3+ regulatory T cells (Treg) [6], 
expression of negative regulatory receptors [7], deletional 
T-cell tolerance [8] and defective T-cell co-stimulation [9]. 
Indoleamine 2,3-dioxygenase 1 (IDO1) is a 
tryptophan-catabolizing enzyme encoded by the IDO1 
gene. IDO1 oxidizes tryptophan into N-formylkynurenine, 
which is rapidly converted to kynurenine by kynurenine 
formamidase [10]. The IDO1-driven production of 
kynurenine promotes the development, stabilization and 
activation of Treg cells, while suppressing effector T cells, 
all of which contribute to immune system impairment in 
cancer-bearing individuals [11]. In humans, IDO1 was 
found to be expressed by a unique subset of dendritic 
cells (DC) [12] and by a variety of solid tumors, such as 
colorectal cancer, melanoma and serous ovarian cancer 
[13-16]. More recently, a dual regulatory function of IDO 
as a catalyst and a signaling protein has been unraveled in 
tolerogenic DC [17].
The expression and function of IDO1 in childhood 
AML have not been previously investigated. Herein, 
we provide evidence that IDO1 is induced in leukemia 
cells by IFN-γ in around half of children with AML 
in a signal transducer and activator of transcription 3 
(STAT3)-dependent manner. IDO-expressing leukemia 
blasts restrain IFN-γ production by allogeneic T cells and 
promote the in vitro differentiation of bona fide Treg cells. 
From a clinical standpoint, IDO1 expression is associated 
with a significantly worse probability of event-free 
survival (EFS).
 RESULTS
Expression of IDO1 in AML blasts
Thirty-seven children with AML (median age 12 
years, range 0.2-23) were retrospectively analyzed for 
IDO status and clinical outcome. Patients’ demographics 
are summarized in Table I. Among the 37 BM samples 
analyzed in this retrospective study, 12 were from children 
with FAB-M1/M2 AML, 9 from children with FAB-M4 
AML, 13 from children with FAB-M5 AML and 1 from 
a child with undifferentiated AML. Details on the FAB 
subgroup were unavailable in 2 children. We initially 
evaluated IDO1 protein levels in leukemia blasts that 
were either maintained in culture medium alone or were 
challenged with IFN-γ for 72 hours. Leukemia cells did 
not express IDO1 constitutively in any BM sample tested 
(Figure 1A), and their basal production of kynurenine was 
barely detectable (data not shown). Overall, treatment 
with IFN-γ for 72 hours translated into the up-regulation 
of functional IDO1 (Figure 1A) and into the long-term 
maintenance of IDO enzyme activity in 51% of AML 
cases, as reflected by heightened production of kynurenine 
(median 22.05 µM/L, range 6.0-36.0, in IFN-γ-stimulated 
cultures compared with 0.85 µM/L, range 0.4-1.7, in 
unstimulated cultures; p<0.0001) and by concomitant 
depletion of tryptophan (median 4.6 µM, range 1-22.6, in 
IFN-γ-stimulated cultures compared with 39.1 µM, range 
18.2-51.0 in unstimulated cultures; p<0.0001; Figure 1B 
and 1C). Figure 1B and 1C also illustrates kynurenine and 
tryptophan levels in serum samples from healthy controls. 
Time-course experiments indicated that kynurenine release 
from IFN-γ-activated AML blasts progressively increased 
over time, reaching maximum levels 48-72 hours after 
the addition of IFN-γ to the cultures (Figure 1D). For the 
purpose of comparison, the release of kynurenine from a 
panel of commercially available AML cell lines is shown 
in Figure 1E, both constitutively and after challenge with 
IFN-γ. Regrettably, the retrospective nature of our study 
precluded the measurement of serum kynurenine and 
tryptophan, an estimate of IDO systemic activity, in the 
37 children with AML that we enrolled [18, 19].
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We also asked whether blast cells from acute 
lymphoblastic leukemia (ALL) of either B-cell or T-cell 
lineage would express IDO1 in either a constitutive and/
or an inducible manner. However, we were unable to 
detect IDO protein and/or kynurenine production and 
tryptophan consumption by any ALL sample tested, either 
at baseline or after in vitro stimulation with IFN-γ (Figure 
1B and 1C), in spite of the ability of IFN-γ to up-regulate 
phosphorylated STAT3 (data not shown).
Interestingly, the IDO-expressing AML cases 
(n=19) were assigned to either the FAB-M4 (8 out of 19 
cases, 42%) or the FAB-M5 subgroup (11 out of 19 cases, 
58%). By contrast, no AML sample of the FAB-M1 and 
FAB-M2 subgroups up-regulated IDO1 in response to 
IFN-γ. Cytogenetics data were available for 36 out of the 
37 children enrolled in this study (Table II). Among the 
13 patients with cytogenetically normal (CN) leukemia, 
only 3 children (23%) were classified as IDO-positive. By 
contrast, 5 AML cases harboring MLL re-arrangements 
and 5 AML cases with inv(16) displayed a FAB-M4/M5 
morphology and up-regulated IDO1 upon treatment with 
IFN-γ (p=0.0065 by the Fisher’s exact test, compared 
Table I: Patients’ demographics and clinical characteristics.
Patient Karyotype/Molecular lesion(s) FAB subgroup Age at diagnosis IDO1 status CR Relapse Alive
UPN #1 Normal M2 13.0 Negative Yes No Yes
UPN #2 t(8;21) (q22;q22) M2 13.0 Negative Yes No Yes
UPN #3 Normal M1 10.0 Negative Yes No Yes
UPN #4 Normal M2 4.9 Negative Yes No Yes
UPN #5 Normal M5 12.0 Negative Yes No Yes
UPN #6 Normal M1 3.0 Negative Yes No Yes
UPN #7 t(8;21) (q22;q22) M2 9.0 Negative Yes No Yes
UPN #8 Normal M1/M2 1.0 Negative Yes No Yes
UPN #9 Normal M2 15.0 Negative Yes No Yes
UPN #10 N.A. M1 15.4 Negative No Yes No
UPN #11 Normal N.A. N.A. Negative No Yes No
UPN #12 FLT3-ITD U 6.0 Negative No Yes Yes
UPN #13 Normal M2 3.4 Negative Yes Yes Yes
UPN #14 t(6;9) - FLT3-ITD M4 23.0 Negative Yes Yes No
UPN #15 Normal M5 15.5 Negative Yes Yes No
UPN #16 t(8;21) (q22;q22) M2 11.3 Negative Yes Yes Yes
UPN #17 t(8;21) (q22;q22) M2 9.0 Negative Yes Yes No
UPN #18 FLT3-ITD N.A. 14.0 Negative N.A. Yes No
UPN #19 t(9;11)(p22;q23) - MLL-AF9 M5 1.0 Positive No No No
UPN #20 t(10;11) - MLL-AF10 M5 6.0 Positive Yes No Yes
UPN #21 inv(16)(p13q22) M4 16.0 Positive Yes No No
UPN #22 t(8;21) (q22;q22) M4 16.0 Positive Yes No Yes
UPN #23 t(10;11) - MLL-AF10 M4/M5 4.0 Positive Yes No Yes
UPN #24 FLT3-ITD M4 12.3 Positive Yes No Yes
UPN #25 inv(16) (p13q22) M4 17.2 Positive Yes No Yes
UPN #26 t(1;11) - MLL-AF1 M5 0.2 Positive Yes No Yes
UPN #27 inv(16)(p13q22) M5 9.0 Positive Yes No Yes
UPN #28 Normal M5 16.5 Positive N.A. No No
UPN #29 FLT3-ITD M5 7.0 Positive No Yes No
UPN #30 Normal M5 14.1 Positive Yes Yes No
UPN #31 FLT3-ITD M5 15.0 Positive Yes Yes No
UPN #32 Normal M5 0.4 Positive Yes Yes Yes
UPN #33 FLT3-ITD M5 12.3 Positive Yes Yes No
UPN #34 inv(16) (p13q22) M4 13.0 Positive Yes Yes Yes
UPN #35 t(10;11) - MLL-AF10 M5 4.0 Positive Yes Yes No
UPN #36 inv(16) (p13q22) M4 0.8 Positive Yes Yes Yes
UPN #37 FLT3-ITD M4 15.7 Positive N.A. Yes No
Legend: UPN = unique patient number; U = undifferentiated AML; N.A. = not available; CR = complete remission; ITD = internal tandem duplication; 
FAB = French-American-British.
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with children with CN leukemia). Among the 5 AML 
cases carrying t(8;21), 4 were IDO-negative. Finally, 
FLT3 internal tandem duplication (ITD), an independent 
prognostic factor for relapse in childhood AML [20], was 
detected in 8 children; leukemia cells of 5 of them (62%) 
were IDO-positive. Collectively, these data show that 
IDO expression segregates within AML cases of myelo-
monocytic origin and is not apparently associated with a 
specific genetic lesion.
Regulation of IDO1 expression in blasts from 
childhood AML
We have previously shown that microenvironmental 
levels of hepatocyte growth factor (HGF), a pro-
angiogenic and immune-modulating cytokine, correlate 
with the expression of functional IDO1 in a subset of 
patients with multiple myeloma, a plasma cell malignancy 
that accounts for approximately 13% of hematological 
cancers in adults and has a unique ability to subvert and/
or escape the anti-tumor immune response [19, 21]. HGF 
is also expressed by half of AML cases, inducing autocrine 
activation of MET receptor [22]. Also, myeloid-derived 
suppressor cells isolated from patients with breast cancer 
express IDO1 in a STAT3-dependent manner [23].
With this rationale in mind, we aimed at getting 
insights into the molecular mechanisms potentially 
implicated in the regulation of IDO1 expression by AML 
blasts. To accomplish this, we pre-treated AML cells 
with either SU11274, a MET inhibitor [19], or WP1066 
(STAT3 Inhibitor III) before their in vitro stimulation 
with IFN-γ. As shown in Figure 2A, IDO mRNA levels 
increased in IFN-γ-challenged AML blasts compared with 
control cultures maintained in the absence of any cytokine 
stimulus, and were unaffected by either STAT3 or MET 
inhibition. In these experiments, 1-methyl-tryptophan 
(1MT), the lead IDO inhibitor compound [24, 25], was 
used as reference. The addition of IFN-γ to leukemia blasts 
also translated into the up-regulation of phosphorylated 
STAT3 (Figure 2B), a phenomenon that was paralleled by 
the increase of IDO1 protein expression (see also Figures 
1B and 1C). A representative Western blot experiment with 
IDO-expressing and IDO-nonexpressing AML samples 
is depicted in Figure 2B. Interestingly, WP1066, but not 
Figure 1: Expression and Function of IDO1 in BM Samples from Children with AML. BM samples from children with AML 
obtained at diagnosis were cryopreserved. After thawing, BM mononuclear cells (MNC) were either stimulated with 100 ng/ml IFN-γ for 
up to 72 hours or were maintained in culture medium alone. Supernatants were collected and used for the measurement of kynurenine and 
tryptophan levels by RP-HPLC. (A) Up-regulation of IDO protein by IFN-γ (+) in 2 representative AML samples; UPN = Unique Patient 
Number; Hsp-70 = heat shock protein-70; (B) Release of kynurenine and (C) Consumption of tryptophan by AML blasts maintained in 
culture for 72 hours with or without exogenous IFN-γ. Blasts from a cohort of 7 children with acute lymphoblastic leukemia (ALL) were 
also challenged with IFN-γ to detect any IDO-mediated tryptophan breakdown. Comparisons between groups were performed with the 
Mann-Whitney U test for paired determinations. HC = healthy controls. Medium = blast cells maintained with complete culture medium 
alone; (D) Time-course experiments with AML blasts from 4 randomly selected BM samples that were either activated with IFN-γ (red 
dots) or left untouched (black dots). Bars depict the median and interquartile range; (E) Commercially available AML cell lines (see main 
text for details) were either stimulated with IFN-γ for 72 hours (black columns) or were maintained in culture medium alone (empty 
columns), prior to HPLC studies. Bars are representative of mean values and standard deviation recorded in 3 independent experiments 
run in duplicate.
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the MET inhibitor SU11274, abrogated the up-regulation 
of IDO1 protein that we observed in response to IFN-γ 
(Figure 2B). In line with this, kynurenine production was 
almost completely hampered in AML blast cells that were 
pre-treated with STAT3, but not with MET inhibitors 
(Figure 2C). The observation that IFN-γ induced the 
up-regulation of phosphorylated STAT3 even in IDO-
nonexpressing AML cells (Figure 2B) implies that failure 
to up-regulate IDO1 by these samples was unlikely to be 
related to a defective IFN-γ signaling circuitry.
In a further set of experiments aimed at assessing 
the possible occurrence of physical interactions between 
IDO1 and STAT3, immunoprecipitates from AML blasts 
were subjected to Western blot runs using IDO1/STAT3-
specific antibodies. The amount of IDO in whole-cell 
extracts (WCE) was determined by immunoblot analysis 
with anti-IDO before immunoprecipitation. As shown 
in Figure 2D, IDO1 and STAT3 proteins were barely 
detectable in immunoprecipitates obtained from lysates 
of AML blasts in the absence of IFN-γ treatment. By 
contrast, IDO1 was up-regulated and coprecipitated with 
STAT3 in AML cells activated with IFN-γ. Taken together, 
these data suggest that STAT3 and IDO1 are interacting 
partners in blasts from childhood AML.
Microenvironmental production of IFN-γ in 
childhood AML
We reasoned that IFN-γ may be the primary 
cytokine stimulus driving in vivo IDO expression in 
childhood AML, in analogy with other normal and tumor 
# of pts
IDO-
positive
IDO-
negative
Normal karyotype 13 3 10*
FLT3-ITD 8 5 3
inv(16) 5 5 0
MLL rearrangement 5 5 0
t(8;21) 5 1 4
*p=0.0065 compared with children harboring inv(16) or MLL 
rearrangement.
Table II: Patients’ cytogenetics
Figure 2: Regulation of IDO1 in AML Blasts. (A) Quantitative RT-PCR and (B) Western blotting studies to detect IDO mRNA 
and protein in primary AML blasts. Samples were pre-treated for 2 hours with either of the following compounds: WP1066 or STAT3 
Inhibitor III (28 µM final concentration), 1-methyl-tryptophan (1MT; 200 µM final concentration), SU11274 MET inhibitor (100 nM 
final concentration), followed by PCR or protein studies. Bars in panel A are representative of the mean ± standard deviation recorded in 
3 independent experiments run in duplicate; (C) Release of kynurenine and depletion of tryptophan in supernatants of AML blasts that 
were pre-treated with either STAT3 inhibitors (WP1066) or MET inhibitors (SU11274) for 2 hours, and then activated with IFN-γ. Control 
cultures were established with either STAT3 inhibitors alone or with MET inhibitors alone. Comparisons were performed with the Mann-
Whitney U test for paired determinations; (D) After challenge with IFN-γ (+) for 16 hours, leukemia cells were lysed, immunoprecipitated 
with anti-STAT3 antibodies and immunoblotted with anti-IDO1 antibodies (upper panel), or they were immunoprecipitated (IP) with anti-
IDO1 antibodies and then immunoblotted with anti-STAT3 antibodies (lower panel). The specificity of each antibody used in these assays 
was confirmed using normal rabbit IgG as a negative control. Western blot runs were also performed with whole cell extracts (WCE).
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cell types [26] and also based on previously published data 
with human AML cell lines [27]. Also, it is conceivable 
that IDO- AML blasts may start expressing IDO when 
exposed to an IFN-γ-rich inflammatory milieu, implying 
that in vivo immune resistance mechanisms centered on 
IDO could be the result of AML blast cell interactions with 
IFN-γ-producing cell types, such as T cells or NK cells.
We initially measured IFN-γ levels in the BM fluid 
of a subgroup of 11 randomly selected children with AML, 
for whom sufficient amounts of surplus diagnostic material 
were available. IFN-γ levels in the BM of IDO-expressing 
AML cases (n=7; median 3.9 ng/ml, range 0.72-8.74) 
exceeded those measured in IDO-nonexpressing AML 
samples (n=4; median 0.97 ng/ml, range 0.8-3.68; 
p=0.047) and in BM blasts from a cohort of 7 children with 
ALL, used as controls (median 1.32 ng/ml, range 0.09-
2.05; p=0.039). We then investigated the propensity of T 
cells infiltrating the BM of children with AML to release 
IFN-γ in response to polyclonal activation. As exemplified 
in Figure 3A-B, intra-tumoral CD4+ and CD8+ T cells 
mainly comprised effector memory (CD45RA-CD62L-) 
and effector T cells (CD45RA+CD62L-). Figure 3C-D 
shows that a median of 16.5% CD4+ and 31.2% CD8+ 
BM-resident T cells from AML patients produced IFN-γ, 
respectively, and suggests that intra-tumoral T cells can 
be an in vivo source of this cytokine in AML. By contrast, 
intracellular IL-4 was detected in a minute percentage of 
CD4+ T cells (median 0.2%); furthermore, the median 
percentage of IL-17-secreting CD4+ T cells was 1.65% 
(Figure 3C-D). Finally, we aimed at enumerating BM-
resident NK cells in children with AML. However, NK 
cells were not abundant in the BM microenvironment 
(data not shown), thus precluding any robust measurement 
of their ability to produce IFN-γ at the single-cell level. 
Effects of IDO1-responsive AML blasts on T-cell 
function
To mimica leukemia-conditioned microenvironment, 
allogeneic CD4+ T cells from healthy donors were co-
cultured with AML blasts that were either pre-activated 
with IFN-γ or left untouched. After 5 days in mixed 
tumor-lymphocyte cultures (MTLC), T cells were assayed 
for the acquisition of FoxP3 expression and for cytokine 
production at the single-cell level. As shown in Figure 
Figure 3: In vitro T-cell Production of IFN-γ. (A) and (B) BM-resident T cells were classified as effector memory (TEM), central 
memory (CM), naïve (N) or effector (TEFF) T cells based on the expression pattern of CD45RA and CD62L, as previously reported [36]. 
Antigen expression patterns in two representative BM samples from children with IDO-expressing AML are shown. BM MNC were first 
gated on CD4+ or CD8 T cells, followed by the quantification of CD62L/CD45RA expression. Quadrant markers were set according to the 
proper isotypic control; (C) and (D) Production of IFN-γ at the single-cell level in 2 representative BM samples from IDO-positive AMLs. 
Details on culture conditions were provided in materials and Methods. BM MNC were first gated on CD4+ or CD8+ T cells, followed by 
the quantification of IFN-γ, IL-4 and IL-17 expression. Markers were set according to the proper isotypic control. The percentage of cells 
staining positively for a given antigen is indicated.
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4A, co-culture with IFN-γ-activated AML blasts resulted 
into an increase of FoxP3-expressing bona fide Treg cells, 
when compared with cultures maintained in the absence of 
leukemia blasts or with those nurtured with a polyclonal 
stimulus, such as PHA, and IL-2, a Treg growth factor 
[28]. The differentiation of FoxP3+ T cells fostered by 
AML blasts was reverted by the addition of 1MT to the 
co-cultures (Figure 4A). 
We also quantitated IFN-γ, IL-17 and IL-4 
production at the single-cell level in T cells that were 
co-cultured with IDO-expressing AML blasts. As shown 
in Figure 4B, AML blasts inhibited IFN-γ production 
both by CD4+ and by CD8+ T cells. Conversely, IL-17 
and IL-4 production were unaffected by IDO-expressing 
AML blast cells. Taken together, MTLCs indicated that 
IDO-expressing AML blasts favor the in vitro emergence 
of potentially leukemia-suppressive Treg cells, while 
restraining IFN-γ production by T cells.
IDO expression correlates with poor survival in 
childhood AML
Data regarding the attainment of complete remission 
(CR) were available for 17 children in the IDO-expressing 
group and for 17 children in the IDO-nonexpressing 
group. Specifically, 15 out of 17 (88%) children with 
IDO-expressing AML entered into CR compared with 
14 out of 17 (82%) children with IDO-nonexpressing 
AML (p=NS by the Fisher’s exact test). Overall, relapse 
occurred in 19 children out of 37 (51%). Among the 19 
children experiencing leukemia relapse, 12 (63%) were 
IDO-positive. In the no-relapse group (n=18), 7 children 
(39%) were IDO-positive. We then aimed at correlating 
IDO status with both disease-free survival (DFS) and 
overall survival (OS). With a median follow-up of 37.4 
months (range 3-80), the 8-year EFS of children whose 
leukemia blasts up-regulated IDO1 in response to IFN-γ 
was equal to 16.4% (SE 9.8), compared with 48.0% (SE 
12.1) in children whose AML blasts were unresponsive 
to IFN-γ (Figure 5; p=0.035). Finally, OS was 31.6% (SE 
15.6) in IDO-expressing cases compared with 63.0% (SE 
12.0) in children with IDO-nonexpressing AML (p=0.1). 
Collectively, these data suggest that children with IDO-
expressing blasts have a worse outcome in comparison to 
children with IDO-nonexpressing AML. 
DISCUSSION
The microenvironment of AML is inherently 
Figure 4: Effects of IDO-Expressing AML Blasts on T-Cell Expression of FoxP3 and on Cytokine Production Profile. 
AML blasts were pre-treated for 2 hours with 200 µM 1MT or were left untouched, followed by stimulation with 100 ng/ml IFN-γ. IDO-
expressing AML blasts were then co-cultured with allogeneic naïve CD4+ T cells in a standard mixed tumor lymphocyte culture (MTLC). 
(A) After 5 days in MTLC, cells were harvested, fixed, permeabilized and labeled with anti-CD25 and anti-FoxP3 mAbs, as detailed in 
Materials and Methods. Control cultures were established with CD4+ T cells and IL-2, either alone or combined with PHA as a polyclonal 
stimulus. Similar results were obtained in 3 independent experiments. The percentage of cells staining positively for a given antigen is 
indicated; (B) After 5 days in MTLC, T cells were activated for 6 hours with a polyclonal stimulus, consisting of PMA and ionomycin, in 
the presence of brefeldin-A to inhibit intracellular protein transport. Cells were then fixed, permeabilized and labeled with cytokine-specific 
mAbs, as detailed in Materials and Methods. The percentage of cells staining positively for a given antigen is indicated. Similar results 
were obtained in 3 independent experiments.
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suppressive for immune effector cells. Patients with AML 
at diagnosis have been reported to harbor dysfunctional T 
and NK cells, partly as a result of the tumor itself [29, 30]. 
In addition, AML-derived DC, AML cell lines and primary 
blasts from adults with AML may all express IDO1, either 
constitutively or after in vitro challenge with IFN-γ [27, 
31, 32]. IDO mRNA has been detected in 52% of adults 
with AML in two different patient series [31, 33]. In the 
first one, AML blasts were found to constitutively express 
an active IDO protein [6, 31]. In the remaining IDO-
negative cases, in vitro challenge with IFN-γ up-regulated 
IDO mRNA, but not IDO protein, suggesting that post-
translational stimuli may be required for the acquisition 
of IDO competency by AML cells [31]. AML patients 
with IDO-positive blasts were shown to have a higher 
frequency of circulating bona fide CD4+CD25+ Treg cells 
compared with patients harboring IDO-nonexpressing 
leukemia blasts. In vitro, IDO-expressing blasts promoted 
the differentiation of Treg cells from naïve T cells, an 
effect that was abrogated by the addition of an IDO 
inhibitor to the co-culture. In the second study on adults 
with AML, IDO mRNA signals were measurable in 13 out 
of 25 (52%) patients [33]. In contrast with the first adult 
series published so far [31], all samples expressing IDO 
mRNA were reported to have detectable IDO activity [33].
Chamuleau and coworkers reported variable 
expression of IDO mRNA in primary blasts from 71 adults 
with AML, with no apparent correlation with cytogenetic 
risk profile or with FAB subtype [34]. Intriguingly, a 
high blast cell content of IDO mRNA was associated 
with lower CR rate (53% versus 84% for patients with 
low IDO expression), shorter relapse-free survival (6.1 
months compared with 24.5 months for patients with 
low IDO expression) and poorer OS (7.4 months vs. 
21.4 months for patients with low IDO expression) [34]. 
However, neither IDO protein levels nor IDO enzymatic 
activity could be evaluated in this study, thus precluding 
any definitive conclusion about the in vivo mechanisms 
than may underlie the different clinical outcome of AML 
patients showing high or low IDO mRNA content in BM 
blasts.
Another study with 184 adult patients with AML 
pointed out that IDO mRNA can be detected in most 
AML samples, irrespective of their FAB subtype [18]. 
Although IDO mRNA levels did not correlate with 
survival in this patient series, those patients with high 
kynurenine/tryptophan ratios (i.e., >0.075) in their 
serum had lower survival rates compared with patients 
with low kynurenine/tryptophan ratios, suggesting again 
that IDO activity affects clinical outcome [18]. In vitro, 
basal production of kynurenine in cultures of AML blasts 
obtained from a subgroup of 15 patients was low in all but 
1 case, and was consistently induced by IFN-γ but not by 
other stimuli, such as TNF-α, PGE
2
 and LPS [18]. Taken 
together, the currently available studies focused on IDO in 
adult AML suggest that IDO is expressed by a subgroup 
of patients and that it may confer an adverse prognosis. 
However, discrepancies are still unsolved concerning the 
mechanisms that govern IDO expression at molecular and 
protein level in AML blasts.
Herein, we present the results of a multi-Centre 
effort aimed at investigating, for the first time, IDO1 
expression and regulation in childhood AML. In our study, 
IDO protein and enzymatic activity were not detected 
constitutively but were induced in 51% of children with 
AML after 72-hour in vitro culture of primary blasts 
with exogenous IFN-γ. The IDO-nonexpressing AML 
cases were equally sensitive to IFN-γ stimulation, as 
suggested by the occurrence of STAT3 phosphorylation. 
This observation implies that IFN-γ signaling is preserved 
in AML cells that do not up-regulate IDO expression in 
response to cytokine stimulation. The ability to increase 
IDO1 expression was unique to AML samples, as we were 
unable to detect IDO protein and/or function in primary 
blasts from childhood ALL of either T or B-cell lineage. 
IDO-expressing AML samples were almost exclusively 
assigned to the FAB-M4/M5 subgroups. By contrast, the 
ability to up-regulate IDO1 in response to IFN-γ was not 
correlated with the cytogenetic risk profile.
Although the microenvironmental source of IFN-γ 
in children with AML remains to be identified, our results 
argue that BM-infiltrating T cells may contribute to IFN-γ 
production which, in turn, has the potential to drive the in 
vivo up-regulation of IDO1 in AML blasts. Our contention 
is backed by the higher levels of IFN-γ measured in the 
BM fluid of patients with IDO-expressing AML. It has 
been reported that IFN-γ production in vivo may result 
from the recognition of melanoma cells by autologous 
CD8+ T cells [35]. This elegant study and our own 
data open an intriguing scenario, whereby the immune 
system, rather than cancer cells themselves, may have 
the intrinsic ability to drive major immunosuppressive 
Figure 5: Kaplan-Meier Estimates of EFS According 
to IDO1 Status. The 8-year EFS was calculated as detailed in 
Materials and Methods. Patients with AML were dichotomized 
based on the IFN-γ-inducible expression of IDO1. N=number; 
E=events; SE=standard error; EFS=event-free survival. 
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pathways. Also, intracellular IFN-γ levels in BM-resident 
T cells from children enrolled in our study correlated 
with the magnitude of the TEM and TEFF compartments, 
both of which lack CD62L expression. This observation 
is in agreement with previous reports showing that IFN-γ 
production is restricted to CD8+ T cells not expressing 
receptors that control homing to secondary lymphoid 
organs, such as CCR7 and/or CD62L [36].
Given the undisputed role of IDO1 in activating 
and stabilizing Treg cells [37], we measured intracellular 
FoxP3 levels after culturing allogeneic naïve T cells with 
IDO-expressing leukemia blasts. Notably, the frequency of 
bona fide Treg cells was higher in co-cultures established 
with IDO-expressing AML blasts. In line with previous 
findings on the ability of IDO-competent myeloma cells 
to tip the Th1/Th2 balance in favor of Th2 cells [19], we 
found that IDO-expressing AML blasts dampened the in 
vitro production of IFN-γ by T cells, an effect that was 
reverted by the IDO chemical inhibitor 1MT.
In conclusion, IDO1 expression is associated 
with poor EFS in childhood AML. Conceivably, IDO-
competent AML blasts may constrain leukemia-specific 
immune responses in vivo through effects on T-cell 
cytokine production and on the emergence of leukemia-
suppressive Treg cells. Strategies to revert immune evasion 
in AML with a T-cell-inflamed BM microenvironment, 
such as targeting of IDO1 and/or STAT3 as negative 
regulatory checkpoints, could be incorporated into current 
treatment protocols for childhood AML [38], especially in 
the setting of minimal residual disease.
PATIENTS AND METHODS
Patients’ characteristics.
Patients were enrolled at 4 different Clinical 
Centers affiliated with the ‘Italian Association of Pediatric 
Hematology/Oncology’ (AIEOP), and were uniformly 
treated according to AIEOP chemotherapy protocols [38, 
39]. Surplus peripheral blood (PB) and/or BM samples 
cryopreserved at time of diagnosis and/or disease relapse 
were used for in vitro studies, as detailed below. Patients 
and/or their legal guardians gave written informed consent. 
The study was approved by the local Ethical Committee 
(protocol #714.12).
Abs and reagents.
FITC-conjugated anti-IDO antibodies (clone 
700838) and recombinant human IFN-γ and IL-2 were 
purchased from R&D Systems (Oxon, Cambridge, 
UK). Rabbit anti-human IDO (H-101) and anti-IRF-1 
(C-20) antibodies, and WP1066 (a STAT3 inhibitor) 
were purchased from Santa Cruz Biotechnology (Milan, 
Italy). The IDO chemical inhibitor d,l-1MT, a racemic 
mixture containing both the levo and the dextro isomer 
of 1MT, L-tryptophan, kynurenine, 3-nitro-L-tyrosine, 
trichloroacetic acid, PMA and ionomycin were obtained 
from Sigma Chemicals (St. Louis, MO). FITC-conjugated 
anti-CD8, anti-IFN-γ, anti-IL-17 and anti-CD14 mAbs, 
PE-conjugated anti-CD56, anti-CD4, anti-CD62L and 
IL-4 mAbs, PerCP-conjugated anti-CD45RA mAbs, 
APC-conjugated anti-CD25 and anti-CD3 mAbs, Cytofix/
Cytoperm™ solution and Golgi Plug Protein Transport 
Inhibitor™ were purchased from BD Biosciences 
(Mountain View, CA). Rabbit anti-human GAPDH 
(D16H11), anti-human β-tubulin (9F3), anti-human 
phosphorylated STAT3 (Tyr705, D3A7) and anti-human 
STAT3 (79D7) antibodies were from Cell Signaling 
Technology (Milan, Italy). Horseradish peroxidase 
(HRP)-conjugated anti-rabbit and anti-mouse secondary 
antibodies were purchased from Bio-Rad (Hercules, CA). 
The Human Regulatory T-Cell Staining Kit was obtained 
from eBioscience (San Diego, CA). KG-1a (a variant sub-
line of KG1 AML cells), NB4 [maturation-inducible AML 
with t(15;17)] and K-562 (chronic myeloid leukemia) cell 
lines were purchased from LGC Standards (Milan, Italy).
Cell and serum preparation.
BM samples were used to isolate mononuclear cells 
by density gradient centrifugation on Ficoll-Hypaque 
(Uppsala, Sweden). Cells were stored in FCS with 10% 
dimethyl-sulfoxide in the vapor phase of liquid nitrogen 
until the day of experimental manipulation.
Intracellular cytokine staining.
Cytokine production at the single-cell level was 
assessed with mAbs directed against IL-4, IL-17 and 
IFN-γ. CD4+ cells were activated for 5 hours with 50 
ng/ml PMA and 1 μg/ml ionomycin, in the presence of 
inhibitors of protein transport. Following fixation and 
permeabilization, cells were labeled with cytokine-specific 
mAbs for 30 minutes at 4°C and then analyzed by flow 
cytometry. 
Real-time quantitative PCR.
Total RNA was obtained from cultured AML cells 
using the RNeasy plus kit (Qiagen, Milan, Italy) according 
to manufacturer’s instructions. Complementary DNA 
(cDNA) was prepared starting from 1 μg of total RNA 
using the iScript cDNA Synthesis Kit (Bio-Rad) according 
to the manufacturer’s instructions. Amplifications were 
carried out using specific primers (IDO1 gene: forward 
primer 5’→3’: GGGACACTTTGCTAAAGGCG; reverse 
primer 5’→3’: GTCTGATAGCTGGGGGTTGC) and the 
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iQ SYBRGreen Supermix (Bio-Rad) in a final volume of 
25 µL, starting with a 3-min template denaturation step 
at 95°C followed by 40 cycles of 15s at 95°C and 1 min 
at 60°C. β-actin was used as housekeeping gene (forward 
primer 5’→3’: GCCGACAGGATGCAGAAGGAG; 
reverse primer 5’→3’: CAGGATGGAGCCGCCGATC). 
Standard curves were generated using a serial dilution of 
the initial amount of control cDNA to determine the range 
of template concentrations, and showed a good linearity 
and efficiency for the different reactions. Melt curves of 
the reaction products were also generated to assess the 
specificity of the measured fluorescence. Samples were 
run in triplicate and the mean of threshold cycles (Ct) 
for each specimen was used to obtain the fold-change of 
gene expression level, using the following equation: fold 
change = 2 - (Ct), where Ct = Ct specific gene-Ct β-actin, 
and (Ct) = Ct specimen-Ct control. Calculations were 
made with the RelQuant Excel spreadsheet (Bio-Rad).
ELISA.
IFN-γ levels in patient serum or in culture 
supernatants were quantitated with a commercially 
available enzyme-linked immunosorbent assay (ELISA; 
R&D Systems). The limit of detection was 15.6 pg/ml 
IFN-γ.
Measurement of Treg cells.
Cells were first labeled with anti-CD4 and anti-
CD25 mAbs, followed by sequential fixation and 
permeabilization, and then were stained with Alexa-Fluor 
488-conjugated anti-FoxP3 mAb (PCH101 clone), as 
already detailed [40].
Western blotting.
AML blast cells (6x105) were centrifuged at 
1,200 rpm for 10 minutes. Cell pellets were lysed with 
RIPA buffer [150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris-HCl (pH=8), 1 
mM PMSF, 1 mM EGTA, 50 mM NaF, 50 mM Na
3
VO
4
 
and protease inhibitors (Roche, Milan, Italy)]. Cell 
lysates were incubated on ice for 20 minutes and clarified 
by centrifugation at 14,000 rpm for 20 minutes. Cell 
extracts were boiled for 5 minutes at 95°C and analyzed 
by 12% SDS-PAGE. Samples were transferred onto a 
nitrocellulose membrane (Bio-Rad, Milan, Italy). Blots 
were probed with primary antibodies at 1:1,000 dilution, 
washed and developed with horseradish peroxidase-
conjugated rabbit or mouse secondary antibodies (Bio-
Rad), respectively. A chemiluminescent Western blotting 
detection reagent was used to reveal the proteins of 
interest (Amersham, Milan, Italy). Densitometry was 
used to quantitate any changes in protein expression levels 
(ImageJ software; National Institutes of Health, Bethesda, 
MD).
Immunofluorescence analysis.
Cells were run through a FACS Canto II® flow 
cytometer (BD Biosciences) with standard equipment. A 
minimum of 30,000 events was collected and acquired in 
list mode using the FACS Diva® software package (BD 
Biosciences).
IDO1 activity.
Tryptophan and kynurenine levels were measured 
with reverse-phase HPLC (Agilent Technologies 1200; 
Waldbronn, Germany). Briefly, 200 µL sample aliquots 
were diluted with 200 µL potassium phosphate buffer 
(0.05 mol/L; pH=6.0) containing 3-nitro-L-tyrosine (100 
µmol/L) as internal standard. Proteins were precipitated 
with 50 µL of 2 mol/L trichloroacetic acid and vials were 
immediately vortex-mixed and centrifuged for 10 minutes 
at 13,000g. One-hundred-fifty µL of the supernatants 
were transferred into micro-vials and placed into the auto-
sampling device (Agilent Technologies 1200). Sample 
were analyzed using a C18HPH ProteCol® HPLC column 
(SGE Analytical Science, Australia) and a double-pump 
HPLC apparatus equipped with spectrophotometric and 
fluorescence detectors (Agilent Technologies). Tryptophan 
was detected by a fluorescence detector at an excitation 
wavelength of 285nm and an emission wavelength of 
365nm. Kynurenine and nitrotyrosine were detected by 
recording UV absorbance at a wavelength of 360nm. 
The concentrations of kynurenine and tryptophan 
were calculated according to the peak height and were 
compared both with 3-nitro-L-tyrosine as internal standard 
and with reference curves constructed with escalating 
concentrations of L-tryptophan (10 to 30 µmol/L) and 
kynurenine (10 to 30 µmol/L).
Co-immunoprecipitation assays.
AML blasts were seeded in 6-well plates at 2 x 
106/mL and were stimulated with 100 ng/ml IFN-γ for 
16 hours. After treatment, cells were harvested, washed 
with ice-cold PBS and lysed with a Co-IP buffer [137 mM 
NaCl, 1% NP-40, 20 mM Tris-HCl (pH=8), 10% glycerol, 
1 mM PMSF, 1 mM CaCl
2
, 1 mM MgCl
2
 50 mM NaF, 
1 mM Na
3
VO
4
 and Protease Inhibitor Cocktail Tablets 
(Roche, Milan, Italy)]. Antibodies to IDO1 (primary 
target antigen) or STAT-3 (interacting protein) were 
conjugated  to Protein A following overnight incubation 
at 4°C (Pierce; Milan, Italy). The antibody-coupled resin 
was incubated with cell lysates (2 mg/sample) for 4 hours 
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at 4°C. Immune complexes were boiled with 30 ml of 
loading buffer (2X) for 5 minutes at 95°C.  Total proteins 
and immune complexes were separated by 10% sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred to nitrocellulose. Membranes 
were blocked with 5% w/v non-fat dry milk and incubated 
with appropriate dilutions of anti-STAT3 or anti-IDO1 
antibodies, following the manufacturer’s instructions. 
Membranes were probed with horseradish peroxidase 
(HRP)-conjugated secondary antibodies and were treated 
with ECL reagent (Euroclone, Milan, Italy). Total cell 
lysates served as a loading control.
Statistical methods.
The approximation of data distribution to normality 
was tested preliminarily using statistics for kurtosis and 
symmetry. Data were presented as median and range, and 
comparisons were performed with the Mann-Whitney 
U test for paired or unpaired data, or with the Kruskal-
Wallis test with Bonferroni’s correction for multiple 
comparisons, as appropriate. Variables related to leukemia 
characterization and prognosis (patient age, leukocyte 
count at diagnosis, FAB classification and molecular 
genetics) were recorded and incorporated into the final 
analysis of the results. Overall survival (OS) and event-
free survival (EFS) were defined as the probability of 
survival, regardless of disease status, and of being alive 
and disease-free at any time point, respectively. The 
8-year OS and EFS for children with acute leukemia were 
calculated with the Kaplan-Meier product limit method, 
using commercially available software packages. The log-
rank test was used to compare differences between groups. 
P values of 0.05 or less denoted statistical significance. 
The Fisher’s exact test was used to compute a P value 
from a contingency table.
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